Ceria-Doped Ni/SBA-16 Catalysts for Dry Reforming of Methane

Ni-ceria nanoparticles (Ni/Ce = 1/1) in the cage-like pores of SBA-16 were prepared and evaluated in methane dry reforming reactions. Coexistence of ceria in NiCe/SBA-16 resulted in forming uniformly sized Ni particles (av. 5.7 nm) within the mesopores of SBA-16, because of the confinement effect from the framework of SBA-16 and the strong interaction between Ni and ceria. Ceria addition facilitated the reduction of NiCe/SBA-16 compared with Ni/SBA-16, and Ce³⁺ was the dominant species in both fresh and used NiCe/SBA-16 catalysts, as determined by Ce L_III-edge X-ray absorption near-edge structure (XANES). The methane conversion was much more stable on NiCe/SBA-16 than on Ni/CeO₂ and Ni/SBA-16 in the methane dry reforming at 973 K during a 100 h reaction period; the deactivation of the Ni catalyst and the collapse of the SBA-16 framework were preferably suppressed for NiCe/SBA-16 under the reaction conditions. The remarkable effect of ceria on the structural stability of both the active Ni particles and the SBA-16 framework led to the consistent catalytic performance of NiCe/SBA-16 in methane dry reforming

Schemata of the systematic review.

<p>Schemata of the systematic review.</p

Enhancer of Zeste Homolog 2 as an Independent Prognostic Marker for Cancer: A Meta-Analysis

<div><p>Background</p><p>Novel biomarkers are of particular interest for predicting cancer prognosis. This study aimed to explore the associations between enhancer of zeste homolog 2 (EZH2) and patient survival in various cancers.</p><p>Methods</p><p>Relevant literature was retrieved from PubMed and Web of Science databases. Pooled hazard ratios (HRs), odds ratios (ORs), and 95% confidence intervals (CIs) were calculated.</p><p>Results</p><p>Forty-nine studies (8,050 patients) were included. High EZH2 expression was significantly associated with shorter overall (hazard ratio [HR] 1.74, 95% CI: 1.46–2.07), disease-free (HR 1.59, 95% CI: 1.27–1.99), metastasis-free (HR 2.19, 95% CI: 1.38–3.47), progression-free (HR 2.53, 95% CI: 1.52–4.21), cancer-specific (HR 3.13, 95% CI: 1.70–5.74), and disease-specific (HR 2.29, 95% CI: 1.56–3.35) survival, but not recurrence-free survival (HR 1.38, 95% CI: 0.93–2.06). Moreover, EZH2 expression significantly correlated with distant metastasis (OR 3.25, 95% CI: 1.07–9.87) in esophageal carcinoma; differentiation (OR 3.00, 95% CI: 1.37–6.55) in non-small cell lung cancer; TNM stage (OR 3.18, 95% CI: 2.49–4.08) in renal cell carcinoma; and histological grade (OR 4.50, 95% CI: 3.33–6.09), estrogen receptor status (OR 0.15, 95% CI: 0.11–0.20) and progesterone receptor status (OR 0.30, 95% CI: 0.23–0.39) in breast cancer.</p><p>Conclusions</p><p>Our results suggested that EZH2 might be an independent prognostic factor for multiple survival measures in different cancers.</p></div

Results of subgroup analysis of pooled hazard ratios of recurrence-free survival and metastasis-free survival of cancer with increased <i>HOTAIR</i> expression.

<p>Results of subgroup analysis of pooled hazard ratios of recurrence-free survival and metastasis-free survival of cancer with increased <i>HOTAIR</i> expression.</p

Results of subgroup analysis of the association between nuclear EZH2 expression and DFS and RFS of multiple cancers.

<p>DFS: disease-free survival; RFS: recurrence-free survival; HR: hazard ratio.</p><p>Results of subgroup analysis of the association between nuclear EZH2 expression and DFS and RFS of multiple cancers.</p

sj-tif-4-tag-10.1177_17562848231165129 – Supplemental material for Neutrophil-to-lymphocyte ratio for predicting postoperative recurrence in Crohn’s disease patients with isolated anastomotic lesions

Supplemental material, sj-tif-4-tag-10.1177_17562848231165129 for Neutrophil-to-lymphocyte ratio for predicting postoperative recurrence in Crohn’s disease patients with isolated anastomotic lesions by Rirong Chen, Chao Li, Kang Chao, Yizhe Tie, Jieqi Zheng, Huili Guo, Zhirong Zeng, Li Li, Minhu Chen and Shenghong Zhang in Therapeutic Advances in Gastroenterology</p

Characteristics of studies included in the meta-analysis.

<p>SI (staining index score): staining intensity x proportion of positively stained cells. OS: overall survival. DFS: disease free survival. MFS: metastasis free survival. LRFS: local recurrence free survival. DMFS: distant metastasis free survival.</p><p>EI: expression index, it was calculated from the formula 1,000 9 2(-DCt), where DCt = Ct (HOTAIR) - Ct (GAPDH). NA: not available.</p><p>*1 denoted as obtaining HRs directly from publications; 2 denoted as calculating HRs from the total number of events and its <i>p</i>-value; 3 denoted as extracting HRs from Kaplan-Meier curves.</p><p>Characteristics of studies included in the meta-analysis.</p

Meta analysis of the independent role of <i>HOTAIR</i> in OS/recurrence/metastasis of different types of cancer.

<p>Meta analysis of the independent role of <i>HOTAIR</i> in OS/recurrence/metastasis of different types of cancer.</p

Results of the meta-analysis of increased EZH2 expression and clinicopathological features of four types of cancer.

<p>OR: odds ratio; ER: estrogen receptor; PR: progesterone receptor; Her-2: human epidermal growth factor receptor 2.</p><p>Results of the meta-analysis of increased EZH2 expression and clinicopathological features of four types of cancer.</p

Meta analysis of the pooled HRs of OS of different types of cancer with increased <i>HOTAIR</i> expression.

<p>(A) Subgroup analysis of HRs of OS by factor of region. (B) Subgroup analysis of HRs of OS by factor of score. (C) Subgroup analysis of HRs of OS by factor of sample size. (D) Subgroup analysis of HRs of OS by factor of type of cancer.</p